SAAP 148 TFA 

SAAP 148 TFA is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 TFA kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 TFA retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 TFA can be used in infection-related research^[1][2][3].

SAAP 148 TFA kills ≥99.9% of planktonic Staphylococcus aureus JAR060131 with an LC_99.9 of 1.6 μM in PBS and 12.8 μM in PBS with 50% human plasma^[1].
SAAP 148 TFA kills ≥99.9% of planktonic Pseudomonas aeruginosa PAO1 with an LC_99.9 of 1.6 μM in PBS and 12.8 μM in PBS with 50% human plasma^[1].
SAAP 148 (1.6-12.8 μM; 24 hours) TFA dose-dependently prevents biofilm formation by Staphylococcus aureus JAR060131, Acinetobacter baumannii RUH875, and both ica-dependent and ica-independent Staphylococcus epidermidis O-47^[1].
SAAP 148 (1.6-102.4 μM; 2 hours) TFA dose-dependently eradicates established biofilms of Staphylococcus aureus JAR060131, Acinetobacter baumannii RUH875, and both ica-dependent and ica-independent Staphylococcus epidermidis O-47^[1].
SAAP 148 (1.6-3.2 μM; 2-4 hours) TFA completely eradicates Staphylococcus aureus JAR060131 persister cells^[1].
SAAP 148 (0.4-3.2 μM; 0.5-120 minutes) TFA rapidly permeabilizes the membranes of Staphylococcus aureus JAR060131 and Acinetobacter baumannii RUH875, leading to complete bacterial killing^[1].
SAAP 148 (0.125-4 μM) TFA strongly perturbs the hydrophobic core of bacterial cytoplasmic membrane-mimicking liposomes and induces complete fluorochrome leakage from POPG liposomes at concentrations ≥2 μM^[1].
SAAP 148 TFA exhibits bactericidal activity against MRSA LUH14616, but its bactericidal efficacy is reduced by interaction with precipitated proteins in plasma or eschar extracts^[3].
SAAP 148 TFA preincubation of SAAP-148 with Novomaix collagen-elastin 3D matrix for 24 h reduces bactericidal activity against MRSA LUH14616, while preincubation with 3% BSA causes an immediate, sustained reduction in efficacy^[3].
SAAP 148 (0-100 nmol; 1 h) TFA induces dose-dependent cytotoxicity in 2D-cultured human fibroblasts and keratinocytes, with 0.23 nmol causing 50% LDH release after 1 h incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SAAP 148 (0.1-1% (w/w); 2000 mg/kg; topical; single dose or daily; 4 hours to 14 days) TFA topical application at concentrations up to 1% (w/w) is safe, with no observable local or systemic adverse effects^[1].
SAAP 148 (0.125-2% (w/w); topical; single dose; 4 hours) TFA single 4-hour topical treatment effectively eradicates acute and established biofilm-associated MRSA and A. baumannii infections in murine abraded skin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3267.06 (free base)

C₁₅₇H₂₆₁N₄₉O₂₇.xC₂HF₃O₂

Solid

White to off-white

Ac-Leu-Lys-Arg-Val-Trp-Lys-Arg-Val-Phe-Lys-Leu-Leu-Lys-Arg-Tyr-Trp-Arg-Gln-Leu-Lys-Lys-Pro-Val-Arg-NH2

Ac-LKRVWKRVFKLLKRYWRQLKKPVR-NH2

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. de Breij A, et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med. 2018;10(423):eaan4044.  [Content Brief]

  [2]. Atif M, et al. Antimicrobial Peptide SAAP-148-Functionalized Hydrogels from Photocrosslinkable Polymers with Broad Antibacterial Activity. Macromol Rapid Commun. 2024;45(24):e2400785.

  [3]. Anna de Breij et al. ,The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms.Sci. Transl. Med.10,eaan4044(2018).